These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 10639353)

  • 21. "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.
    Saito M; Katayama Y; Hishinuma T; Iwamoto A; Aiba Y; Kuwahara-Arai K; Cui L; Matsuo M; Aritaka N; Hiramatsu K
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5024-35. PubMed ID: 24841271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes.
    Peschel A; Vuong C; Otto M; Götz F
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2845-7. PubMed ID: 10991869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.
    Katayama Y; Sekine M; Hishinuma T; Aiba Y; Hiramatsu K
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3730-42. PubMed ID: 27067329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moenomycin-resistance is associated with vancomycin-intermediate susceptibility in Staphylococcus aureus.
    Nishi H; Komatsuzawa H; Yamada S; Fujiwara T; Ohara M; Ohta K; Sugiyama M; Ishikawa T; Sugai M
    Microbiol Immunol; 2003; 47(12):927-35. PubMed ID: 14695442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the effectiveness of common hospital hand disinfectants against methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus, and heterogeneous glycopeptide-intermediate S. aureus.
    Wootton M; Walsh TR; Davies EM; Howe RA
    Infect Control Hosp Epidemiol; 2009 Mar; 30(3):226-32. PubMed ID: 19199533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002].
    Młynarczyk A; Młynarczyk G; Łuczak M
    Med Dosw Mikrobiol; 2003; 55(3):209-17. PubMed ID: 14702662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
    Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
    Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates.
    Boyle-Vavra S; Labischinski H; Ebert CC; Ehlert K; Daum RS
    Antimicrob Agents Chemother; 2001 Jan; 45(1):280-7. PubMed ID: 11120978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.
    Garnier F; Chainier D; Walsh T; Karlsson A; Bolmström A; Grelaud C; Mounier M; Denis F; Ploy MC
    J Antimicrob Chemother; 2006 Jan; 57(1):146-9. PubMed ID: 16286482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autolytic activity and molecular characteristics of Staphylococcus haemolyticus strains with induced vancomycin resistance.
    Kim JW; Chung GT; Yoo JS; Lee YS; Yoo JI
    J Med Microbiol; 2012 Oct; 61(Pt 10):1428-1434. PubMed ID: 22820692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pine oil cleaner-resistant Staphylococcus aureus: reduced susceptibility to vancomycin and oxacillin and involvement of SigB.
    Price CT; Singh VK; Jayaswal RK; Wilkinson BJ; Gustafson JE
    Appl Environ Microbiol; 2002 Nov; 68(11):5417-21. PubMed ID: 12406732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural and topological differences between a glycopeptide-intermediate clinical strain and glycopeptide-susceptible strains of Staphylococcus aureus revealed by atomic force microscopy.
    Boyle-Vavra S; Hahm J; Sibener SJ; Daum RS
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3456-60. PubMed ID: 11083659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus.
    Vaudaux P; Francois P; Berger-Bächi B; Lew DP
    J Antimicrob Chemother; 2001 Feb; 47(2):163-70. PubMed ID: 11157900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
    Neoh HM; Cui L; Yuzawa H; Takeuchi F; Matsuo M; Hiramatsu K
    Antimicrob Agents Chemother; 2008 Jan; 52(1):45-53. PubMed ID: 17954695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS.
    Berscheid A; François P; Strittmatter A; Gottschalk G; Schrenzel J; Sass P; Bierbaum G
    J Antimicrob Chemother; 2014 Dec; 69(12):3190-8. PubMed ID: 25103491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus.
    Pereira PM; Filipe SR; Tomasz A; Pinho MG
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3627-33. PubMed ID: 17646417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options.
    Rybak MJ; Akins RL
    Drugs; 2001; 61(1):1-7. PubMed ID: 11217866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance.
    Boyle-Vavra S; Challapalli M; Daum RS
    Antimicrob Agents Chemother; 2003 Jun; 47(6):2036-9. PubMed ID: 12760894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.
    Hanaki H; Kuwahara-Arai K; Boyle-Vavra S; Daum RS; Labischinski H; Hiramatsu K
    J Antimicrob Chemother; 1998 Aug; 42(2):199-209. PubMed ID: 9738837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.